According to the report published by the Market Research Store, global demand for the gene delivery technologies market was estimated at approximately USD 2,610.8 Million in 2021 and is expected to generate revenue of around USD 4,400.7 Million by the end of 2028, growing at a CAGR of around 15.3% between 2021 and 2028.
Global Gene Delivery Technologies Market: Overview
Gene therapy is defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate use to prevent or alter a specific disease state. The genes and DNA are now being brought in without making use of vectors, and different techniques are being utilized in modifying the function of genes in vivo with no gene transfer. The extent of gene therapy becomes wider, if one adds to this cell therapy, mainly with the use of genetically modified cells. The gene therapy be able to now combined with antisense techniques like RNA interference (RNAi), increasing the therapeutic functions.
Global Gene Delivery Technologies Market: Growth Factor
The global gene delivery technologies market is driven by key factors such as the rising prevalence of chronic diseases, the growing demand for targeted therapies and the rising technological advancements. Besides, other factors expected to stimulate the global market of gene delivery system is the augment in requirement for advanced technologies for targeted systems. Moreover, the launching of innovative and advanced technologies, the increase in demand for self-administration devices for home health care, the growing demand for targeted and the little dose frequency drug delivery, the growth in investment in research and development, and the increase in occurrence of chronic life-threatening diseases are some aspects likely to fuel the global gene delivery technologies market.
| REPORT SNAPSHOT & REPORTING DATA TIMEFRAME |
| Parameter |
Details |
| Historical Date ( Actual Data) |
2016 - 2021 |
| Base Year Data |
2021 |
| Current Year Data |
2021 |
| Projected Data |
2021 - 2028 |
|
Report coverage
|
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
|
|
Segments covered
|
product type, application, region
|
|
Regional scope
|
North America; Europe; Asia Pacific; Central & South America; Middle East & Africa
|
|
Country Scope
|
U.S.; Canada; Mexico; Germany; France; U.K.; China; Japan; South Korea; Singapore; Malaysia; Brazil; Saudi Arabia
|
|
Customization scope
|
Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research needs. Explore purchase options
|
However, the high expenses of the treatment along with the augment in drug recalls owing to severe regulations in rising countries might slow down the growth of the market.
Global Gene Delivery Technologies Market: Segmentation
The global gene delivery technologies market has been segmented into delivery systems, application, and route of administration. On the basis of delivery systems, the global gene delivery technologies market has been classified into viral gene delivery systems, non-viral gene delivery systems, and combined hybrid delivery systems. Based on the application, the global gene delivery technologies market has been categorized into oncology, infectious diseases, pulmonary disorders, cardiovascular disorders, diabetes, and others. In terms of route of administration, the global gene delivery technologies market has been divided into oral, injectable, nasal, and others.
Global Gene Delivery Technologies Market: Regional Analysis
The global gene delivery technologies market has been classified into North America, Europe, Asia-Pacific, Latin America, and the Middle East, and Africa. Globally, North America is leading the global gene delivery system market. North America and Europe together is contributing for significant share of the market, owing to the increase in occurrence of chronic diseases in the United States and Europe and the technological development in drug delivery technologies in this region. The augment in dominance of acute and chronic diseases in the United States is driving the demand for drug delivery systems in the region. The demand for drug and gene delivery system is mounting in this region due to augment in incidence of numerous chronic diseases. Moreover, the Asia Pacific market is anticipated to develop at a rapid rate in the global gene delivery technologies market owing to the boost in prevalence of diseases and the growing investment of major players in the region. Also, the market in the Middle East and Africa is expected to enlarge at a lethargic rate.
Global Gene Delivery Technologies Market: Competitive Players
The foremost market players driving in the global market of gene delivery technologies cover Novartis International AG, Horizon Discovery Group Co., Amgen Inc., QIAGEN, Oxford BioMedia plc, SignaGen Laboratories, SIBIONO, Hoffmann-La Roche AG, Shanghai Sunway Biotech Co. Ltd., Vectalys, Pfizer Inc., Sirion-Biotech GmbH, Bayer AG, Takara Bio Inc., Johnson & Johnson Services Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., System Biosciences, Human Stem Cells Institute, Catalent Inc., OriGene Technologies Inc., Epeius Biotechnologies Corporation, Becton Dickinson and Company, Promega Corporation, and Uniqure NV. These market players implement organic and in-organic growth strategies to develop geographically, enlarge their product offerings, augment customer base, and acquire market share.
Global Gene Delivery Technologies Market: By Delivery Systems
- Viral Gene Delivery Systems
- Non-Viral Gene Delivery Systems
- Combined Hybrid Delivery Systems
Global Gene Delivery Technologies Market: By Application
- Oncology
- Infectious Diseases
- Pulmonary Disorders
- Cardiovascular Disorders
- Diabetes
- Others
Global Gene Delivery Technologies Market: By Route of Administration
- Oral
- Injectable
- Nasal
- Others
Global Gene Delivery Technologies Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
What are the key factors driving global gene delivery technologies market expansion?
The global gene delivery technologies market is driven by key factors such as the rising prevalence of chronic diseases, the growing demand for targeted therapies and the rising technological advancements.
What will be the value of the gene delivery technologies market during 2021 - 2028?
The global demand for the gene delivery technologies market was estimated at approximately USD 2,610.8 Million in 2021 and is expected to generate revenue of around USD 4,400.7 Million by the end of 2028, growing at a CAGR of around 15.3% between 2021 and 2028.
Which region will make notable contributions towards global gene delivery technologies market revenue?
North America and Europe together is contributing for significant share of the market, owing to the increase in occurrence of chronic diseases in the United States and Europe and the technological development in drug delivery technologies in this region.
What are the key players leveraging gene delivery technologies market growth?
The foremost market players driving in the global market of gene delivery technologies cover Novartis International AG, Horizon Discovery Group Co., Amgen Inc., QIAGEN, Oxford BioMedia plc, SignaGen Laboratories, SIBIONO, Hoffmann-La Roche AG, Shanghai Sunway Biotech Co. Ltd., Vectalys, Pfizer Inc., Sirion-Biotech GmbH, Bayer AG, Takara Bio Inc., Johnson & Johnson Services Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., System Biosciences, Human Stem Cells Institute, Catalent Inc., OriGene Technologies Inc., Epeius Biotechnologies Corporation, Becton Dickinson and Company, Promega Corporation, and Uniqure NV.
